Intro Content
Clinical Epigenetics
Re-sensitizing CML to Imatinib: Dual Targeting of HDACs and BCR-ABL with Martinostat
Chronic Myeloid Leukemia (CML), driven by BCR-ABL, accounts for 15% of adult leukemias. While TKIs like imatinib improved outcomes, resistance remains a challenge. We demonstrate for the first time that the HDAC inhibitor martinostat shows potent activity in both TKI-sensitive and -resistant CML.